{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Saeed S"],"funding":["CIHR Canadian Human Immunodeficiency Virus Trials Network","Fonds de recherche du Québec –Santé","Canadian Institutes of Health Research","CIHR"],"pagination":["363-371"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7353326"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["71(2)"],"pubmed_abstract":["Background
High costs of direct-acting antivirals (DAAs) have led health-care insurers to limit access worldwide. Using a natural experiment, we evaluated the impact of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among people living with human immunodeficiency virus (HIV), and then examined who was left to be treated.Methods
Using data from the Canadian HIV-HCV Coinfection Cohort, we applied a difference-in-differences approach. Changes in treatment initiation rates following the removal of fibrosis stage restrictions were assessed using a negative binomial regression with generalized estimating equations. The policy change was then specifically assessed among people who inject drugs (PWID). We then identified the characteristics of "],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus."],"pmcid":["PMC7353326"],"funding_grant_id":["FDN-143270","CTN222"],"pubmed_authors":["Klein MB","Sanche S","Rouleau D","Cote P","Saskatchewan MBK","Gill J","Vachon ML","Pick N","Wong A","Montaner J","Wong L","Barrett L","Hull M","Martel-Laferriere V","Conway B","Strumpf E","Saeed S","Moodie EEM","Sandre R","Rachlis A","Walmsley S","Canadian Coinfection Cohort Study Investigators","Klein M","Tyndall M","Cox J","Moodie E","Sadr A","Haider S","Cooper C","Cohen J"],"additional_accession":[]},"is_claimable":false,"name":"Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus.","description":"Background
High costs of direct-acting antivirals (DAAs) have led health-care insurers to limit access worldwide. Using a natural experiment, we evaluated the impact of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among people living with human immunodeficiency virus (HIV), and then examined who was left to be treated.Methods
Using data from the Canadian HIV-HCV Coinfection Cohort, we applied a difference-in-differences approach. Changes in treatment initiation rates following the removal of fibrosis stage restrictions were assessed using a negative binomial regression with generalized estimating equations. The policy change was then specifically assessed among people who inject drugs (PWID). We then identified the characteristics of ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2026-07-15T23:38:11.863Z","creation":"2025-04-19T11:37:47.823Z"},"accession":"S-EPMC7353326","cross_references":{"pubmed":["31504327"],"doi":["10.1093/cid/ciz833"]}}